Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement PathwaysSeeking Alpha • 10/14/26
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 10/12/26
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 10/12/26
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaGlobeNewsWire • 10/07/26
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead SciencesGlobeNewsWire • 10/05/26
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with PfizerGlobeNewsWire • 09/29/26
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeeking Alpha • 09/17/26
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources OfficerGlobeNewsWire • 08/20/26
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 DegraderGlobeNewsWire • 08/04/26
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaGlobeNewsWire • 08/04/26
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep MomentumZacks Investment Research • 07/23/26
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyGlobeNewsWire • 07/21/26
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 07/09/26
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 07/09/26
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to DeclineZacks Investment Research • 07/01/26
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to TradeZacks Investment Research • 07/01/26